Presentation is loading. Please wait.

Presentation is loading. Please wait.

Complex Coronary Cases Supported by: Abbott Vascular Boston Scientific Corporation Medtronic, Inc. Astrazeneca.

Similar presentations


Presentation on theme: "Complex Coronary Cases Supported by: Abbott Vascular Boston Scientific Corporation Medtronic, Inc. Astrazeneca."— Presentation transcript:

1

2 Complex Coronary Cases Supported by: Abbott Vascular Boston Scientific Corporation Medtronic, Inc. Astrazeneca

3 Disclosures Samin K. Sharma, MBBS, FACC Speaker’s Bureau – Boston Scientific Corporation, Abbott, The Medicines Company, Daiichi Sankyo, Inc. and Lilly USA, LLC Annapoorna S. Kini, MBBS, FACC Nothing to disclose Sameer Mehta, MBBS, FACC Consulting Fees – The Medicines Company American College of Cardiology Foundation staff involved with this case have nothing to disclose

4 Presentation: Presented on 2/8/2013 with cresendo CCS class III angina & exertional dyspnea. Pt had stress MPI revealing severe anterior and lateral ischemia. Echo in past revealed severe MR and minimal LV dysfunction; surgical repair recommended but declined. Cath revealed 3 V CAD and LVEF 55%. SYNTAX score 25. Cardiac surgery recommended but again declined after Heart-Team discussion. Pt underwent Xience Xpedition DES to LCx-HL and prox LAD and did well. Pt Still has residual class II angina. Prior History: Hyperlipidemia, Hypertension, H/o CVA Medications: All once daily dosage Aspirin 81mg, Clopidogrel 75mg, Metoprolol XL 100mg, Diltiazem CD 180mg, Rosuvastatin 20mg March 19th 2013 Case #9: CS, 73 yr M

5 Cardiac Cath 2/8/2013: Left Dominance 3 Vessel CAD with LVEF 56% Left Main: Mild diffuse disease LAD: 80-90% lesion in prox, total D1 fills via collaterals LCx: 90% distal LCx with 80% OM1 bifurcation lesion Ramus Intermedius: 95% lesion, moderate size PCI: Underwent Xience Xpedition DES (3/23mm) to pLAD and Xience Xpedition DES (2.5/28mm) to Ramus Intermedius Plan Today: - PCI of bifurcation lesion of circumflex ( SYNTAX score 16) Case# 9: cont… SYNTAX score 25

6 Appropriateness Criteria for Coronary Revascularization

7 Issues Involving The Case Two DES for bifurcation lesions Newer devices for calcified lesions

8 Issues Involving The Case Two DES for bifurcation lesions Newer devices for calcified lesions

9 Coronary Artery Bifurcation Lesion Interventional Techniques Interventional Bifurcation Techniques One Stent Technique (OST) OST with SBR Dilatation (SBT) Kissing Stent Technique (SKS) ‘T’ Stent Technique (TST) Culotte Stent Technique (CUT) Crush Stent Technique (CrST)

10 MACE TLR % 1S Colombo et al. SES stents (n=85) 13.6 Clinical Outcomes in Trials Comparing One-DES (1S) vs. Two-DES (2S) Strategy in Treating Coronary Bifurcations 1S 2S Pan et al. SES stents (n=91) Steigen et al. NORDIC Trial (n=413) Ferenc et al. T-stenting (n=202) Colombo et al. CACTUS trial (n=85) Hildick et al. BBC ONE (n=500) Sharma et al. PRECISE-SKS (n=100)

11 1S group 2S group % 1S Colombo et al. SES stents (n=85) Clinical Outcomes in Trials Comparing One-DES (1S) vs. Two-DES (2S) Strategy in Treating Coronary Bifurcations 1S 2S Pan et al. SES stents (n=91) Steigen et al. NORDIC Trial (n=413) Ferenc et al. T-stenting (n=202) Colombo et al. CACTUS trial (n=85) Hildick et al. BBC ONE (n=500) Sharma et al. PRECISE-SKS (n=100) Incidence of Reported Stent Thrombosis

12 DKCRUSH Technique for Bifurcation Lesions Chen S et al. J Interven Cardiol 2009;22: st Kissing balloon inflation 5. Final Kissing balloon inflation 1. SBr stenting 2. Balloon crush 4. MV stent and crush

13 Conventional (n= 185) DK Crush (n=185) 9.7 Angiographic Restenosis % A Randomized Clinical Study Comparing Double Kissing Crush With Provisional Stenting for Treatment of Coronary Bifurcation Lesions: DK Crush II Study Main Vessel TVR p= p< p= MACE ST p= p= Chen S et al, JACC 2011;57:914 Side Vessel

14 DK-CRUSH III Study Flowchart of Study Design Chen et al., JACC 2013 In Press

15 DK-CRUSH III Study Chen et al., JACC 2013 In Press TVR-Free Survival Rate at 12 M MACE-Free Survival Rate at 12 M

16 DK-CRUSH III Study: Clinical F/U at 12 Months Chen et al., JACC 2013 In Press % p=0.001 p=1.00 p=0.38 p=0.03 p=0.62 Culotte Group (N = 209) DK Group (N = 210)

17 DK-CRUSH III Study Chen et al., JACC 2013 In Press Forest Plots of 1-Year MACE Rate in Pre-Specifies Subgroups

18 Sirker et al., JACC Cardiovasc Interv 2013;6:139 BBC One Study: 9-Month Post-PCI Scores on SAQ for Simple and Complex Groups

19 Sirker et al., JACC Cardiovasc Interv 2013;6:139 BBC One Study: Direction of Change in Individual Patients’ Scores on SAQ

20 Issues Involving The Case Two DES for bifurcation lesions Newer devices for calcified lesions

21 Facts about Calcified Lesions 1.Angiography underestimates the presence, extent and axial depth of calcium 2.Calcium significantly increases procedural complications 3.Most studies have excluded calcified lesions 4.While rotational atherectomy (RA) allows for greater stent expansion, studies have reported increased late loss and restenosis, likely due to platelet activation and thermal injury from the device 5.Thus, at the present time, RA is mainly reserved for undilatable or extremely calcified lesions. Mintz et al., Circ 1995;01:1959, Lofberg et al., Cardiovasc Interv Radiol 1998;19:317, Davies et al., J Am Coll Surg 2005;201:275, Gallino et al., Circ 1984;70:619, Becquemin et al., J Endovasc Surg, 1995;2:42, Zdanowski et al., Int Angio 1999;18:251, Vroegindeweij et al., Cardiovasc Interv Radiol 1997;20:420

22 Généreux, TCT 2012 Impact of Severity of Coronary Calcification on 1- Year Outcomes After PCI in NSTEMI/STEMI: Insight from an angiographic pooled analysis from ACUITY and HORIZONS Trials

23 Frequency of Moderate/Severe Calcification in ACS Population n = 6,855 patients Généreux, TCT 2012 Moderate/Severe None/Mild

24 1-Year Ischemic Outcomes: ACS Population (N= 6855 patients) % Généreux, TCT 2012 p= p=0.001 p=0.22 p=0.007 p=0.002 p=0.001 None/Mild Moderate/Severe

25 Device Selection for Various Coronary Lesions Type * Compliant or Non-compliant Balloon All Comers/Fibrotic Undilatable/Mild-Mod Calcified Heavily Calcified AngioSculpt

26 Balloon Atherotomy Cutting Balloon (Flextome) Longitudinal microtomes - Security & performance are engineered to: Reduce vessel wall expansion Maximize plaque compression Relief hoop stress - Better results with lower inflation pressure compared to plain old balloon angioplasty AngioSculpt balloon Indications: -Mild calcified -Inelastic/chronic -Ostial -ISR

27 Post-procedure Stent Luminal Area ≥5.0 mm 2 Costa et al., Am J Cardiol 2007;100:812 % p=<0.001

28 Stent Expansion by Plaque Morphology Pre-dilatation with AngioSculpt Pre-dilatation with POBA Direct Stent Soft Calcific Fibrotic Mixed % Optimal Stent Expansion Costa et al., Am J Cardiol 2007;100:812

29 ROTAXUS 240 patients with calcified lesions enrolled between August 2006 and March 2010 at 3 clinical sites in Germany 1:1 randomization Rotoblator + PES (n=120) PTCA + PES (n=120) Clinical follow-up at 9 months in 96.2% (n=227) Angio follow-up at 9 months in 80.5% (n=190) IVUS not used Mean age 71 DM 28% MVD 74% Ostial 18% Bifurc 48% B2/C 90% Richert, TCT 2011 *Primary endpoint: In-stent late loss - 2 patients died in-hospital - 6 patients withdrew consent - 5 patients lost at follow-up

30 ROTAXUS: 9-month Follow-up % Richert, TCT 2011 * Defined as death, MI and TVR p=0.78 p=0.79 p=0.73 p=0.84 p=0.46 p=1.0 ROTA + PES (n=123) PTCA + PES (n=132)

31 ORBITAL ATHERECTOMY: Unique Mechanism of Action Differential Orbital Sanding Crown will only sand the hard components of plaque Soft components (plaque/tissue) flex away from crown Orbital Mechanism Increased speed = Increased centrifugal force Greater centrifugal force = Larger orbital diameter CF=Mass X Rotational speed 2 Radius of the orbit

32 Orbital Atherectomy Technology for Calcified Coronary Arteries Easy setup and use Control of device in operating field.012” OAS guide wire Compatible with 6 French guiding catheters

33 ORBITAL Atherectomy: Unique Mechanism of Action Orbiting Crown Enables Continous flow of blood and saline Minimizes thermal injury Potentially decreases no-reflow and periprocedural cardiac enzyme elevation One crown treats different vessel diameters based on orbiting speed

34 The Differences Between Sanding and Drilling OrbitalRotational Mechanism of Action Direction Bi-directional Uni-directional

35 ORBIT I Trial First-in-man study using orbital atherectomy in coronary arteries Designed to demonstrate safety and performance in calcified coronary lesions Prospective, single-arm 2 centers OUS 50 subjects with >90 ⁰ of calcium via IVUS Compared to ORBIT II Shorter lesions Less B2/C lesions MACE Rate 30 days 1 6 months 1 2 years 2 3 years 2 6%8%15%18.2% Cardiac Death0%2%6%9.1% Q-wave MI0% Non Q-wave MI6% 9%9.1% TLR2% 3% 1.Parikh et al., Catheter Cardiovasc Interv 2012, March 5 2. Parikh et al., JACC Cardiovasc Interv 2013;6:Suppl 5

36 Chambers, ACC 2013 ORBIT II Study Design To evaluate safety and efficacy of coronary OAS to prepare de novo severely calcified coronary lesions for enabling stent placement Prospective Multi-center trial Single arm – FDA recommendation as there are no FDA- approved percutaneous treatments for patients with severely calcified lesions. 443 patients enrolled in 49 US sites 30 days follow-up Complete in 97.7 % (N=430/443)

37 Chambers, TCT 2012 ORBIT II Study Design Primary Safety Endpoint: 30-Day MACE  Cardiac death  MI defined as CK-MB level > 3 times upper limit of lab normal (ULN) value With or without abnormal Q-wave  Target vessel revascularization (TVR) Primary Efficacy Endpoint: Procedural Success  Success in facilitating stent delivery with a final residual stenosis of <50% and without in-hospital MACE

38 Chambers, TCT 2012 The ORBIT II Trial: An Historic Coronary Study Unique Study Design to Evaluate Higher Risk CAD Patients EF < 35% INCLUDED DIALYSIS PATIENTS INCLUDED SEVERELY CALCIFIED ARTERIES ORBIT II Study

39 Chambers, ACC 2013 The ORBIT II Trial: Primary Safety Endpoint 30 Day MACE Rate Components: MI (CK-MB >3x ULN):9.7% Non Q-wave 8.8% Q-wave0.9% TVR/TLR:1.4% TVR 0.7% TLR 0.7% Cardiac death: 0.2% 80% 85% 90% 95% 100% Freedom from 30 Day MACE = 89.8% Performance Goal = 83% 95% CI = 87.0%, 92.7%

40 Chambers, ACC 2013 The ORBIT II Trial: Primary Efficacy Endpoint Procedural Success Components: Successful Stent Delivery:97.7% Less than 50% residual stenosis: 98.6% In-hospital MACE: 9.5% MI (CK-MB >3x ULN)/TVR/TLR: 9.3% Non- Q-wave 8.6% Q-wave 0.7% TVR 0.7% Cardiac death: 0.2% 80% 85% 90% 95% 100% Procedural Success = 89.1% Performance Goal = 82% 95% CI = 85.8%, 91.8%

41 Chambers, ACC 2013 The ORBIT II Trial: 30 Day Results (N=443) Patients with Severely Calcified Coronary Lesions Underwent Diamondback 360 ⁰ Orbital Atherectomy at 49 States Primary Efficacy Endpoint of Procedural Success % Primary Safety Endpoint of Freedom from MACE Successful <50% In-hospital MI TVR Cardiac stent residual MACE death delivery stenosis %

42 Take Home Message: Two stent strategy and devices for calcified lesions Appropriately done 2 stent treatment strategy is emerging as the superior strategy over 1 stent in large coronary bifurcation lesions. Hence no longer the issue should 1 or 2 DES; rather we should identify lesions which will need 2 DES and plan accordingly (rather then bailout strategy) Orbital atherectomy system in heavily calcified coronary lesions appears very promising and once available, has a chance for wider acceptance because of effectiveness and simple setup and easy learning curve.

43 DK-Crush technique has shown to be superior to other stent strategy for bifurcation lesions except : A. Lower restenosis B. Lower TVR C. Lower MACE D. Lower stent thrombosis Question # 1

44 Orbital atherectomy trials have shown 9-12M MACE rate of: A. 6-10% B % C % D % E. >25% Question # 2

45 Statement about mechanism of Orbital atherectomy is true: A. Lumen gain is proportional to the size of the burr B. Lumen gain is proportional to burr movement C. Lumen gain is proportional to the burr speed Question # 3

46 DK-Crush technique has shown to be superior to other stent strategy for bifurcation lesions except : A. Lower restenosis B. Lower TVR C. Lower MACE D. Lower stent thrombosis Question # 1 The correct answer is D. While DK Crush trials have shown lower MACE and restenosis, thee has been no difference in the incidence of stent thrombosis.

47 Orbital atherectomy trials have shown 9-12M MACE rate of: A. 6-10% B % C % D % E. >25% Question # 2 The correct answer is A. Both ORBIT I and II trials showed MACE rate of <10% at 1 year follow-up. All was largely due to small non-Q wave MI.

48 Statement about mechanism of Orbital atherectomy is true: A. Lumen gain is proportional to the size of the burr B. Lumen gain is proportional to burr movement C. Lumen gain is proportional to the burr speed Question # 3 The correct answer is C. Lumen gain after Orbital atherectomy is dependent on the burr speed; faster it is, more arc it covers and larger is the lumen gain.


Download ppt "Complex Coronary Cases Supported by: Abbott Vascular Boston Scientific Corporation Medtronic, Inc. Astrazeneca."

Similar presentations


Ads by Google